1ohr
|
VIRACEPT (R) (NELFINAVIR MESYLATE, AG1343): A POTENT ORALLY BIOAVAILABLE INHIBITOR OF HIV-1 PROTEASE
OverviewOverview
Using a combination of iterative structure-based design and an analysis of, oral pharmacokinetics and antiviral activity, AG1343 (Viracept, nelfinavir, mesylate), a nonpeptidic inhibitor of HIV-1 protease, was identified., AG1343 is a potent enzyme inhibitor (Ki = 2 nM) and antiviral agent (HIV-1, ED50 = 14 nM). An X-ray cocrystal structure of the enzyme-AG1343 complex, reveals how the novel thiophenyl ether and phenol-amide substituents of, the inhibitor interact with the S1 and S2 subsites of HIV-1 protease, respectively. In vivo studies indicate that AG1343 is well absorbed orally, in a variety of species and possesses favorable pharmacokinetic properties, in humans. AG1343 (Viracept) has recently been approved for marketing for, the treatment of AIDS.
About this StructureAbout this Structure
1OHR is a Single protein structure of sequence from Human immunodeficiency virus 1 with 1UN as ligand. The following page contains interesting information on the relation of 1OHR with [HIV-1 Protease]. Full crystallographic information is available from OCA.
ReferenceReference
Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease., Kaldor SW, Kalish VJ, Davies JF 2nd, Shetty BV, Fritz JE, Appelt K, Burgess JA, Campanale KM, Chirgadze NY, Clawson DK, Dressman BA, Hatch SD, Khalil DA, Kosa MB, Lubbehusen PP, Muesing MA, Patick AK, Reich SH, Su KS, Tatlock JH, J Med Chem. 1997 Nov 21;40(24):3979-85. PMID:9397180
Page seeded by OCA on Thu Nov 8 14:22:44 2007